Clal Biotechnology Industries
Venture Capital
Active
Tel Aviv, Israel
23
21M
17
0.88
4
0.26
9
- Stages of investment
- Areas of investment
Summary
Clal Biotechnology Industries is the famous VC, which was founded in 1998. The company was established in Asia in Israel. The main office of represented VC is situated in the Ramat Gan.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Sight Diagnostics, Cadent Therapeutics, Elicio Therapeutics We can highlight the next thriving fund investment areas, such as Medical Device, Pharmaceutical. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - Israel.
The usual things for fund are deals in the range of 10 - 50 millions dollars. This Clal Biotechnology Industries works on 12 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2013. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 2 percentage points less often commits exit comparing to other organizations. The average startup value when the investment from Clal Biotechnology Industries is 100-500 millions dollars. The increased amount of exits for fund were in 2018.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Clal Biotechnology Industries, startups are often financed by Yissum Technology Transfer Company of the Hebrew University, Auriga Partners, Ziegler Meditech Equity Partners. The meaningful sponsors for the fund in investment in the same round are Yissum Technology Transfer Company of the Hebrew University, Pontifax, Technion Research & Development Foundation. In the next rounds fund is usually obtained by Yissum Technology Transfer Company of the Hebrew University, Wellington Management, Technion Research & Development Foundation.
We also calculated 2 valuable employees in our database.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 23
- Lead investments
- 4
- Exits
- 9
- Rounds per year
- 0.88
- Follow on index
- 0.26
- Investments by industry
- Health Care (21)
- Biotechnology (18)
- Medical Device (13)
- Medical (8)
- Pharmaceutical (7) Show 20 more
- Investments by region
-
- Israel (17)
- United States (6)
- Peak activity year
- 2013
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Avg. valuation at time of investment
- 102M
- Group Appearance index
- 0.91
- Avg. company exit year
- 11
- Avg. multiplicator
- 4.04
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Sight Diagnostics | 01 Nov 2014 | Artificial Intelligence, Machine Learning, Health Care, Health Diagnostics, Medical Device, Medical, Computer Vision | Early Stage Venture | 6M | Tel Aviv District, Tel Aviv-Yafo, Israel |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.